Across TCGA pan-cancer cohorts, LINC02870 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LINC02870 data layer compared with 28 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher LINC02870 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC02870 expression acts as an unfavorable survival marker.
LUSC and LGG are the cancer types where LINC02870 Mutation most reproducibly stratifies survival.